Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-04-13 4:30 pm Purchase | 13G | Protagonist Therapeutics, Inc. PTGX | ADAGE CAPITAL PARTNERS GP L.L.C. | 2,955,000 5.44% | 1,804,955 (+156.95%) | View |
| 2023-03-20 5:04 pm Purchase | 13G | Protagonist Therapeutics, Inc. PTGX | BIOTECHNOLOGY VALUE FUND L P | 5,025,900 9.6% | 3,775,900 (+302.07%) | View |
| 2023-02-14 4:11 pm Sale | 13G | Protagonist Therapeutics, Inc. PTGX | Point72 Asset Management L.P. | 368,006 0.7% | -2,052,303 (-84.80%) | View |
| 2023-02-14 10:04 am Purchase | 13G | Protagonist Therapeutics, Inc. PTGX | RTW INVESTMENTS LP | 3,591,986 7.3% | 992,164 (+38.16%) | View |
| 2023-02-13 6:19 pm Sale | 13G | Protagonist Therapeutics, Inc. PTGX | BIOTECHNOLOGY VALUE FUND L P | 1,250,000 2.5% | -3,641,945 (-74.45%) | View |
| 2023-02-09 4:54 pm Purchase | 13G | Protagonist Therapeutics, Inc. PTGX | Farallon Capital Partners L.P. | 5,055,102 9.99% | 5,055,102 (New Position) | View |
| 2023-02-09 11:30 am Purchase | 13G | Protagonist Therapeutics, Inc. PTGX | VANGUARD GROUP INC | 3,097,714 6.3% | 3,097,714 (New Position) | View |
| 2023-01-31 1:58 pm Purchase | 13G | Protagonist Therapeutics, Inc. PTGX | BlackRock Inc. BLK | 3,652,157 7.4% | 370,521 (+11.29%) | View |
| 2023-01-11 1:00 pm Unchanged | 13G | Protagonist Therapeutics, Inc. PTGX | JOHNSON & JOHNSON JNJ | 2,449,183 4.98% | 0 (Unchanged) | View |
| 2023-01-10 08:18 am Sale | 13G | Protagonist Therapeutics, Inc. PTGX | STATE STREET CORP STT | 3,792,926 7.71% | -2,983,343 (-44.03%) | View |
| 2023-01-03 4:22 pm Purchase | 13G | Protagonist Therapeutics, Inc. PTGX | CITADEL ADVISORS LLC | 2,682,814 5.5% | 2,682,814 (New Position) | View |
| 2022-12-12 08:41 am Sale | 13G | Protagonist Therapeutics, Inc. PTGX | FMR LLC | 385,863 0.784% | -3,168,232 (-89.14%) | View |
| 2022-07-11 11:51 am Purchase | 13G | Protagonist Therapeutics, Inc. PTGX | STATE STREET CORP STT | 6,776,269 13.93% | 4,204,699 (+163.51%) | View |
| 2022-06-10 11:04 am Sale | 13G | Protagonist Therapeutics, Inc. PTGX | FMR LLC | 3,554,095 7.304% | -3,293,182 (-48.09%) | View |
| 2022-02-14 4:34 pm Sale | 13G | Protagonist Therapeutics, Inc. PTGX | Point72 Asset Management L.P. | 2,420,309 5.1% | -1,908,721 (-44.09%) | View |
| 2022-02-14 1:57 pm Sale | 13G | Protagonist Therapeutics, Inc. PTGX | Consonance Capital Management LP | 0 0% | -2,729,709 (Position Closed) | View |
| 2022-02-14 08:07 am Sale | 13G | Protagonist Therapeutics, Inc. PTGX | RTW INVESTMENTS LP | 2,599,822 5.4% | -1,050,247 (-28.77%) | View |
| 2022-02-11 9:03 pm Purchase | 13G | Protagonist Therapeutics, Inc. PTGX | BIOTECHNOLOGY VALUE FUND L P | 4,891,945 9.99% | 616,980 (+14.43%) | View |
| 2022-02-11 4:18 pm Sale | 13G | Protagonist Therapeutics, Inc. PTGX | FARALLON CAPITAL MANAGEMENT LLC | 3,417,134 6.9% | -507,866 (-12.94%) | View |
| 2022-02-10 3:41 pm Purchase | 13G | Protagonist Therapeutics, Inc. PTGX | STATE STREET CORP STT | 2,571,570 5.39% | 2,571,570 (New Position) | View |